前瞻性阿片类药物减量干预对根治性前列腺切除术后处方与使用的影响:ORIOLES 计划结果
干预使出院后阿片处方量由 224.3 mg 降至 120.3 mg(-46.4%,P=0.01),阿片使用量由 52.1 mg 降至 38.3 mg(-26.5%,P<0.01),并提高阿片处置率(+13.5%,P<0.01)。
要点
- 基于手术特异性指南与教育的干预可显著降低根治性前列腺切除术后出院阿片处方量与使用量。
- 出院时阿片处方量较大、体重指数较高及术前使用阿片药物与出院后阿片使用量增加独立相关。
- 干预后仅 2.2% 患者因术后疼痛需额外用药,1.3% 开始长期使用阿片药物。
核心结论
- 基于证据的前瞻性干预降低了根治性前列腺切除术后出院阿片处方与使用,同时提高处置率。
- 研究识别了出院后阿片使用增加的相关危险因素。
- 结果支持将循证阿片减量干预扩展至其他外科专科。
研究设计与样本
- 前瞻性、非随机、前后对照干预试验,作为 ORIOLES 计划的一部分。
- 干预前组 214 例、干预后组 229 例,随访率 100%。
- 干预措施包括出院说明、护理教育与标准化处方指南。
主要发现
- 出院后阿片处方量由 224.3 mg 降至 120.3 mg(-46.4%,P=0.01)。
- 阿片使用量由 52.1 mg 降至 38.3 mg(-26.5%,P<0.01)。
- 阿片处置率提高 13.5%(P<0.01)。
- 出院时阿片处方量较大、体重指数较高、术前使用阿片药物与出院后阿片使用量增加独立相关;慢性疼痛病史差异无统计学意义。
- 干预后队列中 2.2% 因术后疼痛需额外用药,0.9% 获得处方,1.3% 开始长期使用。
关键数值与推荐
- 主要结局为根治性前列腺切除术后总口服吗啡当量(OMEQ)使用量。
- 次要结局包括阿片处方、处置、额外阿片药物需求及术后 30 天切口/腹部疼痛。
- 干预前后处方量 224.3 mg 对 120.3 mg(-46.4%,P=0.01),使用量 52.1 mg 对 38.3 mg(-26.5%,P<0.01),处置率+13.5%(P<0.01)。
临床怎么用
- 可在根治性前列腺切除术围手术期采用手术特异性指南、出院说明与护理教育组合减少出院阿片处方。
- 出院时应评估出院阿片处方量、体重指数及术前阿片使用等风险因素以个体化镇痛与随访。
- 应同步强化阿片处置教育,减少家庭剩余阿片药物。
- 该模式可考虑推广至其他外科专科。
局限性
- 研究为非随机前后对照设计,可能存在时间趋势与混杂偏倚。
- 单中心或特定计划背景下结果外推需谨慎(原文未明确中心数量)。
- 随访至术后 30 天,长期阿片使用数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the effect of a prospective opioid reduction intervention after radical prostatectomy (RP; based on a surgery-specific guideline and education) on post-discharge opioid prescribing, use, disposal, and need for additional opioid medication. PATIENTS AND METHODS: A prospective, non-randomised, pre-post interventional trial of patients undergoing RP for prostate cancer (August 2017-November 2018) was conducted as part of the Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery (ORIOLES) Initiative. An evidence-based intervention including: a discharge sheet, nursing education, and standardised prescribing guideline, was applied with the primary outcome of total oral morphine equivalents (OMEQ) used after RP. Secondary outcomes included opioid prescribing, opioid disposal, need for additional opioid medication, and presence of incisional/post-surgical abdominal pain at 30 days after RP. RESULTS: A total of 214 (Pre-Intervention arm) and 229 (Post-Intervention arm) adult patients were enrolled (100% follow-up). The intervention reduced post-discharge opioid prescribing (from 224.3 to 120.3 mg; -46.4%, P = 0.01), reduced opioid use (from 52.1 to 38.3 mg; -26.5%, P < 0.01), and increased opioid disposal (+13.5%, P < 0.01). Greater prescribing of opioids at discharge, higher body mass index, and use of opioid medication prior to surgery, were independently associated with greater post-discharge opioid use, while history of a chronic pain diagnosis was not statistically significant. In the Post-Intervention cohort, 2.2% of patients needed additional medication for post-surgical pain (0.9% obtained a prescription) and 1.3% initiated long-term use. CONCLUSIONS: A prospective, evidence-based intervention reduced post-discharge opioid prescribing and use, while increasing disposal after RP. Risk factors for increased opioid use were identified. The results support expanding the use of evidence-based opioid reduction interventions to other surgical specialties.
引用
- Patel HD, Faisal FA, Patel ND, et al. Effect of a prospective opioid reduction intervention on opioid prescribing and use after radical prostatectomy: results of the Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery (ORIOLES) Initiative. BJU Int. 2019. PMID: 31643128. doi:10.1111/bju.14932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。